Unveiling the Impact of Transparency in Coverage Data on Healthcare Prices

By HEOR Staff Writer

October 30, 2023

The Role of Transparency in Coverage Data

In the realm of healthcare, the importance of transparency cannot be overstated. A recent study by Benjamin L. Chartock, PhD; Kosali Simon, PhD; Christopher M. Whaley, PhD, has shed light on how transparency in coverage (TiC) data can significantly influence prices for common healthcare services. The researchers examined TiC price data from Humana, a major national insurer in the USA, highlighting the potential uses of such data for future research.

Unravelling Price Variation

The study’s findings revealed substantial price variation for common healthcare services. The researchers focused on seven procedures, including both ‘shoppable’ and ‘non-shoppable’ services. Interestingly, the variation in prices for these services was similar, regardless of their ‘shoppability’. The study also noted that mean county-level prices were lowest in the central US and Florida, with higher prices observed in the upper-Midwest and Southeast.

The findings of the study make a compelling case for the necessity of further research into the factors that drive price variation in healthcare. The topic of whether or not these prices accurately reflect worth, or whether or not they are an indication of inequalities in market power and negotiation leverage, will need to be investigated more in the future. If the second possibility is correct, then there is an even greater requirement for regulations that guarantee competitive healthcare markets.

In conclusion, the study highlights the potential of informed healthcare consumerism as a lever for managing costs and enhancing patient happiness. It also opens up new possibilities for the use of TiC data in larger settings, which opens up new avenues for using TiC data.

Reference url

Recent Posts

Strengthening Supply Chains: The EU Critical Medicines Act

By João L. Carapinha

May 12, 2026

The European Medicines Agency (EMA) has welcomed the provisional political agreement on the EU Critical Medicines Act, an initiative designed to enhance the availability, production, and supply of critical medicines throughout the European Union. This agreement represents a key a...
Marstacimab Cost-Effectiveness Analysis in Hemophilia Treatment: A Portuguese Assessment
The public assessment report for Hympavzi (marstacimab) in Portugal concludes that the product offers no added therapeutic value relative to recombinant factor VIII concentrates and emicizumab in patients aged 12 years and older weighing at least 35 kg with severe hemophilia A without factor VIII...
Overcoming Challenges in Managed Entry Agreements for ATMPs
Decision-makers in England, the Netherlands, and Spain consistently identify administrative burden, outcome measurement, and data collection as the foremost obstacles to adopting managed entry agreements ATMPs. These challenges emerge most acutely when hybrid or outcome-based agreements are consi...